Trade Ocugen, Inc. - OCGN CFD
Add to favourite- Summary
- Historical Data
Spread | 0.0066 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 0.6847 |
Open | 0.7191 |
1-Year Change | -42% |
Day's Range | 0.7 - 0.7353 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 23, 2025 | 0.7135 | 0.0166 | 2.38% | 0.6969 | 0.7435 | 0.6969 |
Apr 22, 2025 | 0.6847 | 0.0118 | 1.75% | 0.6729 | 0.6999 | 0.6729 |
Apr 21, 2025 | 0.6740 | 0.0091 | 1.37% | 0.6649 | 0.6779 | 0.6499 |
Apr 17, 2025 | 0.6789 | 0.0290 | 4.46% | 0.6499 | 0.6850 | 0.6499 |
Apr 16, 2025 | 0.6509 | -0.0192 | -2.87% | 0.6701 | 0.6701 | 0.6354 |
Apr 15, 2025 | 0.6951 | 0.0182 | 2.69% | 0.6769 | 0.7069 | 0.6610 |
Apr 14, 2025 | 0.6706 | -0.0382 | -5.39% | 0.7088 | 0.7355 | 0.6519 |
Apr 11, 2025 | 0.6832 | 0.0163 | 2.44% | 0.6669 | 0.7289 | 0.6354 |
Apr 10, 2025 | 0.6694 | -0.0038 | -0.56% | 0.6732 | 0.6734 | 0.6368 |
Apr 9, 2025 | 0.6897 | 0.1094 | 18.85% | 0.5803 | 0.7143 | 0.5669 |
Apr 8, 2025 | 0.5795 | -0.0544 | -8.58% | 0.6339 | 0.6521 | 0.5788 |
Apr 7, 2025 | 0.6368 | 0.0399 | 6.68% | 0.5969 | 0.6625 | 0.5769 |
Apr 4, 2025 | 0.6587 | 0.0528 | 8.71% | 0.6059 | 0.6853 | 0.6037 |
Apr 3, 2025 | 0.6355 | -0.0120 | -1.85% | 0.6475 | 0.6616 | 0.6169 |
Apr 2, 2025 | 0.6829 | 0.0360 | 5.57% | 0.6469 | 0.7069 | 0.6269 |
Apr 1, 2025 | 0.6440 | -0.0429 | -6.25% | 0.6869 | 0.7136 | 0.6318 |
Mar 31, 2025 | 0.6984 | -0.0440 | -5.93% | 0.7424 | 0.7605 | 0.6769 |
Mar 28, 2025 | 0.7901 | 0.0882 | 12.57% | 0.7019 | 0.7960 | 0.6970 |
Mar 27, 2025 | 0.7170 | -0.0194 | -2.63% | 0.7364 | 0.7364 | 0.6870 |
Mar 26, 2025 | 0.7332 | 0.0063 | 0.87% | 0.7269 | 0.7347 | 0.6998 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Ocugen, Inc. Company profile
Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine.
Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.
Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.
The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).
The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD).
Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.
Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.
Ocugen is headquartered in Malvern, Pennsylvania.
Industry: | Biotechnology & Medical Research (NEC) |
11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US
News

ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com